Clinical Trials · NCT00046137

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

CompletedPhase 3Teriparatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
0
Start date
Not specified
Locations
13 sites, United States
Primary endpoint
Study in Osteoporosis, Postmenopausal
View Teriparatide compound reference